Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01380093 · ClinicalTrials.gov registry record · Phase 1
Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT01380093 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 80 participants.
The verdict
NCT01380093, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine the abuse potential of EMBEDA compared to controlled release morphine when crushed and taken orally by non-dependent recreational opioid users; secondary purposes include to determine the abuse potential of crushed EMBEDA relative to placebo and and to compare the pharmacokinetics and safety of crushed EMBEDA with crushed controlled-release morphine and crushed placebo.
Interventions
- DRUG Placebo
- DRUG MS Contin (morphine sulfate, controlled release)
- DRUG EMBEDA (morphine sulfate / naltrexone hydrochloride)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2011-02 |
| Est. Completion | 2011-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01380093
The ClinicalTrials.gov registry entry for NCT01380093 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01380093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01380093 about?
NCT01380093 is a clinical study titled "Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users". The primary purpose of this study is to determine the abuse potential of EMBEDA compared to controlled release morphine when crushed and taken orally by non-dependent recreational opioid users; secondary purposes include to determine the abuse potential of crushed EMBEDA relative to placebo and and ...
What is the current status of trial NCT01380093?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2011-02. Estimated completion is 2011-05.
What interventions are being tested in trial NCT01380093?
The interventions under investigation include: Placebo (DRUG), MS Contin (morphine sulfate, controlled release) (DRUG), EMBEDA (morphine sulfate / naltrexone hydrochloride) (DRUG).
Who is sponsoring clinical trial NCT01380093?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.